1
May 2024
Apollon Formularies
Plc
("Apollon" or the
"Company")
Intention to Withdraw from
AQUIS
London, England - Apollon Formularies PLC
(AQSE: APOL), an innovator in medical cancer research,
announces that it intends to
withdraw its ordinary shares from trading on the Aquis Growth
Market, with the last day of trading expected to be 3 June 2024, subject to shareholder
approval.
The Company continues to
progress the divestment of its intellectual property, proprietary
formulations and other assets associated with its cancer research
business to a Canadian company in the same field, as announced on
21 November 2023. Further information
will be available in the Company general meeting circular, referred
to below. However, Apollon can no longer support the high cost of
being a quoted company while this process is
concluding.
The Company is preparing
and will shortly post a general meeting circular to shareholders
who will in due course be asked to vote on a withdrawal resolution
from the Aquis Growth
Market.
There will be no
alternative exchange or platform to trade the Company's ordinary
shares once withdrawal has taken place, however, the Company will
explore potential mechanisms for the ongoing sale and purchase of
its ordinary shares using platforms tailored to unlisted companies.
It has not yet identified such a
platform.
The directors of the
Company accept responsibility for the contents of this
announcement.
For additional
information, please visit www.apollon.org.uk or
contact:
Apollon
Formularies
Tel:
+44 771 198 0221
Stene
Jacobs stene@apollon.org.uk
Peterhouse Capital
Limited (Corporate Adviser)
Tel:
+44 207 220 9795
Guy
Miller
gm@peterhousecapital.com
About Apollon and Apollon
Jamaica
Apollon Formularies
plc is an international medical cannabis and medicinal
mushroom pharmaceutical company. Apollon Formularies Jamaica
Limited is a pharmaceutical company incorporated and operating
in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican
government's Cannabis Licensing Authority (CLA) to
cultivate (R&D), perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis to treat various illnesses under medical
supervision.